Type 1 Gaucher disease is currently categorized as non-neuronopathic, although recent studies suggest peripheral neurological manifestations. We report prevalence and incidence data for peripheral neuropathy and associated conditions from a multinational, prospective, longitudinal, observational cohort study in patients with type 1 Gaucher disease, either untreated or receiving enzyme replacement therapy. The primary outcome parameters were the prevalence and incidence of polyneuropathy, evaluated by standardized assessments of neurological symptoms and signs, and electrophysiological studies. All diagnoses of polyneuropathy were adjudicated centrally. Secondary outcome parameters included the prevalence and incidence of mononeuropathy, other neurological or electrophysiological abnormalities not fulfilling the criteria for a mono-or polyneuropathy and general type 1 Gaucher disease symptoms. Furthermore, a literature search was performed to identify all studies reporting on prevalence and incidence of polyneuropathy in the general population. One hundred and three patients were enrolled [median (range) age: 42 (18-75) years; disease duration: 15 (0-56) years; 52% female]; 14 (13.6%) were untreated and 89 (86.4%) were on enzyme replacement therapy. At baseline, 11 patients [10.7%; 95% confidence interval (CI): 5.9-18.3] were diagnosed with sensory motor axonal polyneuropathy. Two (1.9%; 95% CI: 0.1-7.2) had a mononeuropathy of the ulnar nerve. The 2-year follow-up period revealed another six cases of polyneuropathy (2.9 per 100 person-years; 95% CI: 1.2-6.3). Patients with polyneuropathy were older than those without (P50.001). Conditions possibly associated with polyneuropathy were identified in four patients only, being monoclonal gammopathy, vitamin B 1 deficiency, folic acid deficiency, type 2 diabetes mellitus, renal insufficiency, alcohol abuse and exposure to toxins related to profession. The 11 cases of polyneuropathy found at baseline were confirmed during follow-up. According to the literature, the prevalence of polyneuropathy in the general population was estimated between 0.09 and 1.3% and the incidence was estimated between 0.0046 and 0.015 per 100 person-years. Thus, we conclude that the prevalence and incidence of polyneuropathy in patients with type 1 Gaucher disease is increased compared with the general population.
Introduction
Gaucher disease is one of the most common glycosphingolipid storage disorders, with an estimated global prevalence of 1 : 200 000 (Cox and Schofield, 1997) . Impaired activity of the lysosomal enzyme, b-glucocerebrosidase, leads to build-up of glucosylceramide in macrophages, forming lipid-engorged 'Gaucher cells' that accumulate primarily in the liver, spleen, bone, lungs and the nervous system (Beutler, 1997; Grabowski and Horowitz, 1997) . Unlike in the rare type 2 and 3 phenotypes, the absence of neurological symptoms is traditionally considered mandatory for a diagnosis of type 1 Gaucher disease. However, emerging data suggest that neurological manifestations could be considered part of the type 1 Gaucher disease phenotype.
A recent systematic review of the literature identified 86 reports in which patients with type 1 Gaucher disease, or carriers of a glucocerebrosidase gene mutation, were described with some form of neurological manifestation. In addition, a cohort of 75 type 1 Gaucher disease patients was retrospectively investigated for the prevalence of neurological manifestations. Thirtyfour neurological diagnoses were made and 45 patients reported at least one neurological symptom during the median follow-up time of 11 years. Paraesthesias were the most frequently mentioned complaint (Biegstraaten et al., 2008) . This high prevalence of neurological symptoms is supported by the findings of an epidemiological survey of patients with type 1 Gaucher disease undergoing long-term enzyme replacement therapy. This survey revealed that 73% of patients had at least one neurological symptom, including paraesthesias, tremor, muscular weakness, muscle cramps and sciatica, most of which were thought to be due to peripheral nervous system disease (Pastores et al., 2003) . A case-control survey in 107 patients with type 1 Gaucher disease (untreated or receiving enzyme replacement therapy) and 104 controls corroborated these findings, reporting a significantly higher frequency of all of the following peripheral neuropathyrelated symptoms among the patients: loss of feeling, pins and needles, tingling, shooting pains, muscle weakness, cold sensation, hands 'fall asleep' and not stable on feet (Halperin et al., 2007) . However, the above-mentioned studies were limited by the absence of a neurological examination and standardized electrophysiological assessment. A study in 31 patients with type 1 Gaucher disease revealed three patients with polyneuropathy confirmed by electrophysiological assessment. Electrophysiological assessment was carried out in only half of the studied patients (15 out of 31), and the selection criteria for patients to have this test were not made clear (Capablo et al., 2008) . Thus, contrary to the classical non-neuronopathic phenotypical description, peripheral nervous system manifestations appear to be of particular relevance in type 1 Gaucher disease, but available data do not permit a reliable estimate of the prevalence and incidence of peripheral neuropathy in type 1 Gaucher disease.
The occurrence of peripheral neuropathy in type 1 Gaucher disease is of specific interest following observations of two cases during a clinical trial with the substrate reduction therapy, miglustat (Zavesca TM , Actelion Pharmaceuticals, Basel, Switzerland) (Cox et al., 2000 (Cox et al., , 2003 ; relatedness to treatment was unconfirmed due to the absence of baseline neurological and electrophysiological assessment. As part of a post-marketing surveillance commitment of Actelion to the European Medicines Evaluation Agency in relation to the registration of miglustat, a multicentre study was undertaken to investigate comorbidities in type 1 Gaucher disease, with a special focus on peripheral neuropathy. The study was done under the auspices of the European Working Group on Gaucher Disease. Here, we report baseline and 2-year follow-up data from this study, with the principal aim of determining the prevalence and incidence of polyneuropathy in type 1 Gaucher disease. Additional aims were to evaluate the prevalence and incidence of mononeuropathy, other neurological or electrophysiological abnormalities not fulfilling the criteria for a mono-or polyneuropathy, and standard type 1 Gaucher disease manifestations. Finally, a literature search was performed on the prevalence and incidence of polyneuropathy in the general population, for comparison with the study data.
Materials and methods

Design
This 2-year prospective, longitudinal, observational cohort study was conducted in eight centres across seven countries in Europe. The primary outcome parameters were the prevalence and incidence of polyneuropathy, evaluated by standardized assessments of neurological symptoms and signs in conjunction with standardized electrophysiological assessment. Additional outcomes included the prevalence and incidence of mononeuropathy, other neurological or electrophysiological abnormalities not fulfilling the criteria for a mono-or polyneuropathy, general type 1 Gaucher disease symptoms and assessments of associated conditions. All diagnoses of peripheral neuropathy were adjudicated centrally.
The data from the observational cohort study were compared with data obtained from 25 healthy subjects who were assessed using identical methodology to the current study including equally standardized electrophysiological assessment at the Academic Medical Centre in Amsterdam. A comparison was also made with data obtained after a systematic review of the literature. To this end, Medline and Embase were searched to identify all studies reporting on prevalence and incidence of polyneuropathy in the general population between 1960 and 2009.
Patients
Eligible adult patients (aged 18 years) diagnosed with type 1 Gaucher disease by glucocerebrosidase assay or molecular genetic analysis, attending routine clinical visits and receiving either no treatment or enzyme replacement therapy were enrolled between 3 May 2005 and 28 December 2006. Those with a history of oculomotor gaze palsies, ataxia or other manifestations associated with type-3 disease were excluded. Patients were also excluded if they were undergoing or had undergone treatment with miglustat or an investigational agent.
All patients provided written informed consent before participation. The study protocol was approved by independent local ethics committees and was conducted in accordance with the Declaration of Helsinki (1964) and subsequent revisions.
Assessments
Patients were initially screened for entry by the assessment of medical history (including Gaucher disease history) and concurrent medical conditions and comorbidities. Special attention was given to conditions and comorbidities that are related to, or may cause, polyneuropathies, such as diabetes and alcohol use. Concomitant therapies were fully documented. In addition, all patients underwent laboratory investigations including vitamin B 12 , vitamin B 1 , folic acid, creatinin, total protein and electrophoresis. Homocysteine and methylmalonic acid were measured in a central laboratory. A vitamin B 12 deficiency was defined as an increase in homocysteine above the top of the reference ranges of 6-15 mM/l for pre-menopausal females and 8-18 mM/l for males and post-menopausal females, and of methylmalonic acid levels 40.4 mM/l; elevations of these parameters indicate vitamin B 12 deficiency at the tissue level. Glucose levels were measured in all patients diagnosed with polyneuropathy, eventually followed by glucose and HbA1c during fasting.
All patients underwent assessments of systemic Gaucher disease manifestations including liver and spleen volume measurement either by computed tomography, magnetic resonance imaging or ultrasound, and Gaucher cell infiltration of bone marrow measured by magnetic resonance imaging, and/or bone mineral density measured by dual-energy X-ray absorptiometry. Chitotriosidase levels were measured in a central laboratory.
On study entry, and every 6 months thereafter, all patients underwent a systematic neurological assessment of symptoms and signs. In addition, all patients underwent standardized electrophysiological assessment at baseline. Electrophysiological assessment was repeated when new symptoms and/or signs appeared, or when existing symptoms worsened during the 2-year follow-up period. Furthermore, all patients diagnosed with a polyneuropathy at baseline underwent a repeated electrophysiological assessment at 24 months. Disability was evaluated using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale (Merkies et al., 2002) .
'Polyneuropathy' was defined as a diffuse, generally symmetrical, length-dependent disease of two or more nerves, in contrast to 'mononeuropathy' where only one nerve is involved. Diagnoses of mono-or polyneuropathy were confirmed only in patients with clinical neurological symptoms and/or signs compatible with peripheral neuropathy in combination with electrophysiological abnormalities.
Neurological assessment of symptoms and signs
Clinical neurological symptoms were assessed using a neurological symptom survey, a questionnaire-based evaluation used to assess symptoms according to a standardized protocol. Patients were asked whether they had experienced the following symptoms for periods of at least 1 week either unilaterally or bilaterally in the hands, arms, legs and feet: burning sensations, decreased sense of touch, tingling, shooting pains, limb falling asleep, trembling, muscle spasms, unsteadiness on feet, pins and needles, cold sensation, electric shock feelings, muscle weakness and muscle stiffness. This extensive questionnaire was used with the aim of detecting all patients with potential peripheral nerve disease, accepting that many would turn out not to have peripheral nerve involvement (high sensitivity, low specificity). Clinical neurological signs were evaluated by examination of muscle strength, deep tendon reflexes and sensation. Muscle strength was assessed using the standard Medical Research Council scale (Kleyweg et al., 1991) . Sensory modalities were assessed with the INCAT sensory sum score (Merkies et al., 2000) .
Symptoms and signs were assessed by certified neurologists who were trained by the central assessor before study site initiation and were considered to be due to polyneuropathy only if they were present in a symmetrical distribution with a proximal-to-distal gradient and confirmed by electrophysiological abnormalities.
Electrophysiological assessment
Electrophysiological assessment consisted of nerve conduction studies and electromyography according to standardized methodology being conducted by certified neurophysiologists at each centre (Donofrio and Albers, 1990) .
Electrophysiological data for each patient were compared with normative and cut-off values from the laboratory at which the measurement took place to ascertain if findings were normal or abnormal, and if abnormal findings were compatible with the definition of a polyneuropathy. Further standardization between laboratories was not judged to be necessary, as the data were not required for use in any statistical calculations. Electrophysiological abnormalities confined to one nerve, especially nerve conduction slowing or compound muscle action potential reduction over common entrapment sites, were considered to be compatible with a mononeuropathy. An electrophysiological diagnosis of polyneuropathy required more or less symmetric abnormalities in more than two nerves with the legs being more affected than the arms, i.e. evidence of a diffuse and length-dependent nerve disease. American Academy for Emergency Medicine criteria for demyelination were used to distinguish between axonal and demyelinating polyneuropathy (Olney, 1999) .
All results of electrophysiological studies were evaluated centrally in a two-step process. First, copies of the full reports were assessed in a blinded fashion (i.e. with no access to clinical signs or symptoms or other patient data, apart from age and gender) by the independent central reviewer. This resulted in four categories: (i) normal electrophysiological studies; (ii) abnormal electrophysiological studies fulfilling the criteria for a polyneuropathy; (iii) abnormal electrophysiological studies fulfilling the criteria for a mononeuropathy; and (iv) abnormal electrophysiological studies that were considered to be minor, i.e. either one abnormal parameter in one nerve or more than one parameter not within the same nerve at the lower or upper limit of normal.
Secondly, the central reviewer evaluated these findings in the context of all available clinical data and formulated a final diagnosis.
This resulted in the following six categories: (i) patients with no evidence for peripheral nerve disease (normal or only minor abnormal electrophysiological studies and no symptoms or signs); (ii) patients with symptoms and signs unrelated to peripheral nerve disease (normal or only minor abnormal electrophysiological studies but symptoms and signs present); (iii) patients with a definite polyneuropathy (abnormal electrophysiological studies fulfilling the criteria for a polyneuropathy with symptoms or signs compatible with a polyneuropathy); (iv) patients with a sub-clinical polyneuropathy (abnormal electrophysiological studies fulfilling the criteria for a polyneuropathy but without symptoms or signs); (v) patients with a mononeuropathy (abnormal electrophysiological studies fulfilling the criteria for a mononeuropathy with symptoms or signs compatible with a mononeuropathy); and (vi) patients with a sub-clinical mononeuropathy (abnormal electrophysiological studies fulfilling the criteria for a mononeuropathy but without symptoms or signs).
Assessment of prevalence and incidence of polyneuropathy in the general population
First, a cohort of 25 healthy subjects was assessed using identical methodology to the current study including equally standardized electrophysiological assessment (both conducted and reviewed in a blinded manner by the same assessor as for the observational cohort study) at the Academic Medical Centre in Amsterdam. These subjects were investigated during the past 5 years as part of a natural history study in hereditary motor and sensory neuropathy type 1a patients, and hence were not formally part of the protocol of the cohort study (Verhamme et al., 2009) .
Secondly, a literature search was performed to identify all studies reporting on prevalence and incidence of polyneuropathy in the population. Medline and Embase were searched ) using the keywords 'polyneuropathies', 'peripheral neuropathy', 'prevalence', 'occurrence' and 'epidemiology'. Eligibility was determined by reading the abstract, followed by the 'Materials and Methods' section if the paper was considered relevant. References listed in eligible papers and in review articles were searched. Papers that met the following criteria were selected: (i) original data, prospectively or retrospectively collected; (ii) a predefined definition of polyneuropathy, or reproduction of data in such a way that polyneuropathy cases could be identified. In the latter case, the most strict definition possible was used; (iii) reporting on true polyneuropathies, which means that in papers reporting on 'peripheral neuropathies', either polyneuropathies were mentioned separately or the description of cases suggested distal symmetric neuropathy; (iv) case-control studies, in which controls were healthy or randomly sampled; (v) human studies only; (vi) focus on adults, but population-based studies reporting on children and adults were eligible as well; (vii) English, Dutch, French or German language publications.
Sample size and data analysis
The cohort study is an observational study in a rare disease, and as such the sample size was chosen on pragmatic grounds. The aim was to recruit at least 100 patients with type 1 Gaucher disease in order to generate a reliable prevalence estimate for peripheral neuropathy in terms of two-sided 95% CIs constructed using the adjusted Wald method (Agresti and Caffo, 2000) . Descriptive summaries of the data are based on the 'all-enrolled' study population. The prevalence of mono-and polyneuropathy was determined from all patients who underwent both clinical neurological examinations and electrophysiological assessment. Prevalence is given as a percentage with a 95% CI. The incidence was calculated as the number of new cases divided by the calculated sum of follow-up years of all included patients. Incidence is given as the number of cases per 100 person-years with a 95% CI. All other results are expressed by median and ranges. Characteristics of patients with polyneuropathy were compared with those of patients without polyneuropathy. Differences between variables were tested using the Mann-Whitney U-test and differences in proportions were tested using Fisher's exact test.
Data were collected by Actelion Pharmaceuticals Ltd, sponsor of the study. The full-study database was released by Actelion to three of the authors (M.B., C.E.M.H. and I.N.vS.) in order to analyse the data and write the manuscript.
To generate from the selected literature a pooled estimate of the prevalence of polyneuropathy in the general population, the numbers of polyneuropathy cases were extracted from each eligible study. Subdivisions were made on the basis of diagnostic criteria (signs only, symptoms and signs, electrophysiological studies and symptoms and/or signs with electrophysiological confirmation) and study type (hospital-, general practitioner-and population-based studies and case-control studies). The pooled estimate of the prevalence was calculated by combining individual study data using the study size as weight and is given as a percentage with the 95% CI constructed using the adjusted Wald method (Agresti and Caffo, 2000) .
Results
Patient population
All patients with a confirmed diagnosis of type 1 Gaucher disease were asked to participate in this study. From a total of 104 patients screened for inclusion, 103 patients were enrolled; one patient withdrew after screening due to an inability to commit to follow-up assessments. Patient characteristics are summarized in Table 1 . One hundred and two patients attended at least one follow-up visit. Of the 103 enrolled patients, 96 (93%) completed the follow-up. Two patients withdrew due to starting treatment with miglustat, one patient was non-compliant and the other four patients requested withdrawal from the study.
The healthy comparator subjects had a median (range) age of 48 (33-72) years, and this cohort consisted of 11 males and 14 females.
Prevalence of peripheral neuropathy at baseline
At baseline, a total of 11 patients (10.7%; 95% CI: 5.9-18.3), nine receiving enzyme replacement therapy, were confirmed as having sensory motor axonal polyneuropathy on the basis of electrophysiological abnormalities and the presence of neurological symptoms and/or signs both compatible with a polyneuropathy. Details of the results of neurological screening for each of the Mononeuropathy of the ulnar nerve at the elbow was found in two patients (1.9%; 95% CI: 0.1-7.2). One of these two patients was a frequent tennis player; the other patient did not have a history of trauma, arthritis or repetitive strain injury that could explain his mononeuropathy.
A total of 22 patients (21.4%) showed clinical symptoms and/or signs compatible with peripheral neuropathy, but did not have any electrophysiological abnormalities (Table 2) . Conversely, electrophysiological abnormalities were recorded in a total of 23 patients (22.3%) who did not show clinical symptoms and/or signs compatible with peripheral neuropathy. Of these 23 patients, 19 had only minor abnormalities but 4 (3.9%) had electrophysiological abnormalities of a severity compatible with a polyneuropathy and were considered by the central assessor as being in the sub-clinical phase of developing a polyneuropathy ( Table 2 ).
The conclusions of electrophysiological studies did not change during the two-step assessment of peripheral nerve disease.
Results of follow-up study
Follow-up studies revealed six new cases (2.9 per 100 personyears; 95% CI: 1.2-6.3) of polyneuropathy. Details of the results of neurological assessments are given in Table 2 . No new cases of mononeuropathy were found.
Among the 11 patients who were diagnosed with polyneuropathy at baseline, 4 (36%) showed worsening of electrophysiological abnormalities. The electrophysiological test results of the remaining 7 patients remained unchanged during the follow-up period.
Two of the 22 patients (9%) with symptoms and/or signs compatible with neuropathy but without electrophysiological confirmation developed polyneuropathy according to the predefined definition. Among the 19 patients without symptoms and/or signs but with minor electrophysiological abnormalities, 4 patients (21%) developed polyneuropathy. Only 1 of the 4 patients who were considered to be in the sub-clinical phase of developing a polyneuropathy had follow-up electrophysiological studies. This patient did not develop a polyneuropathy. The other 3 patients did not have any symptoms or signs at repeated neurological assessments during follow-up, and thus repeated electrophysiological assessment was not considered necessary.
Other neurological abnormalities
The neurological symptom survey showed at least one neurological symptom in 50 patients (49%). INCAT sensory sum scores and Medical Research Council sum scores indicated minimal impairment in most patients (data not included). The median sum of the INCAT arm and leg disability scale score was greater (indicating more severe disability) in polyneuropathy patients (1, range 0-5) than in nonpolyneuropathy patients (0, range 0-3) (P50.001). For both groups, these scores indicate that there were few patients with symptoms in the arms, and that the ability to use zips and buttons, wash or brush hair, hold a knife and fork together and handle small coins was not affected. Walking was generally not affected, and patients whose walking was affected could walk independently outdoors. None of the polyneuropathy patients used pain medication for neuropathic pain.
Characteristics of patients with polyneuropathy
Given these results, patients with polyneuropathy were considered mildly affected. Patients diagnosed with polyneuropathy (n = 17) were generally similar to those without polyneuropathy (n = 86), although patients with polyneuropathy were older than nonpolyneuropathy patients (P50.001) ( Table 3) .
Among the 17 patients diagnosed with polyneuropathy, 4 had conditions other than Gaucher disease that could possibly be associated with polyneuropathy: 2 patients (both with genotype N370S/rare allele) had monoclonal gammopathy; 1 of these 
Prevalence and incidence of polyneuropathy in the general population
In the 25 healthy subjects, the same diagnostic procedure as for the patients with type 1 Gaucher disease was followed to establish mono-or polyneuropathies. The neurological symptom survey data showed at least one neurological symptom in 6 subjects (24%), of whom 3 (12%) had unilateral and 3 (12%) had bilateral symptoms. Unilateral muscle weakness of one muscle was established in 1 subject, 3 had decreased deep tendon reflexes and 5 had an INCAT sensory score that indicated mild sensory deficit. Two cases of mononeuropathy (8%) and no cases of polyneuropathy were found in these healthy subjects. , 63 patients for vitamin B 1 and 102 patients for homocysteine and methylmalonic acid; b Occurring in 430% of patients. GD1 = type 1 Gaucher disease; ERT = enzyme replacement therapy; ns = not significant. Normal ranges: plasma chitotriosidase, 4-120 nmol/ml.h; methylmalonic acid, 50.4 mMol/l; homocysteine, pre-menopausal females, 6-15 mMol/l, males and post-menopausal females, 8-18 mMol/l.
The literature search identified two population-based studies (Mygland and Monstad, 2001; Rudolph and Farbu, 2007) and nine case-control studies (Rosé n et al., 1978; Lehtinen et al., 1989; MacKenzie et al., 1989; Vrethem et al., 1993; Parry et al., 1997; Albers et al., 2004; Lopate et al., 2006; Chroni et al., 2007; Obermann et al., 2008) that closely resembled the design of our study since a definition of polyneuropathy as symptoms and/or signs in combination with electrophysiological abnormalities was applied. The two population-based studies revealed a pooled estimated prevalence of chronic symmetric symptomatic polyneuropathy of 0.09% (95% CI: 0.08-0.10). The pooled estimate for the prevalence of polyneuropathy in the case-control studies was 1.3% (95% CI: 0.5-3.2). The studies using a less strict definition of polyneuropathy (symptoms and signs compatible with polyneuropathy) estimated the prevalence of polyneuropathy between 1.0% and 3.7% (Osuntokun et al., 1982; Bharucha et al., 1987 Bharucha et al., , 1991 Beghi et al., 1988; Franklin et al., 1990; al Rajeh et al., 1993; IGPSG, 1995; The ILSA Working Group, 1997; Beghi and Monticelli, 1998; Oluwole et al., 2000; Zarrelli et al., 2001; Teunissen et al., 2002; Leite et al., 2003; Tapp et al., 2003; Daousi et al., 2004; Davis et al., 2004; Watters et al., 2004; Baldereschi et al., 2007; Manschot et al., 2008; Ziegler et al., 2008) . See Supplementary material for a full list of studies on the prevalence of polyneuropathy in the general population.
Incidence rates of polyneuropathy have been reported in three studies. A large retrospective, general practitioner-based study revealed an incidence of polyneuropathy (all excluding diabetic and alcoholic subjects) of 0.015 per 100 person-years (95% CI: 0.009-0.023). A diagnosis was made when clinical objective signs and abnormal electrophysiological results consistent with the diagnosis were recorded in a general practitioner database (MacDonald et al., 2000) . Another retrospective cohort study, based on data from general practices in the UK, revealed an incidence rate of 0.0046 per 100 person-years (95% CI: 0.0013-0.0118). The source population consisted of patients of 40-74 years old. A diagnosis of polyneuropathy was made when symptoms or absent Achilles tendon reflexes were recorded by the general practitioner, a consultant neurologist confirmed the diagnosis or electrophysiological studies were performed (Gaist et al., 2001) . Finally, a multi-centre community-based prospective study revealed an incidence of non-diabetic polyneuropathy of 0.58 per 100 person-years (95% CI: 0.43-0.78) (Baldereschi et al., 2007) . Diagnosis was made on the basis of the presence of symptoms and signs.
The incidence of electrophysiologically confirmed polyneuropathy is thus low: between 0.0046 and 0.015 per 100 person-years. Even when only symptoms and signs are used as an indication of polyneuropathy, the incidence remains low (0.58 per 100 person-years).
Discussion
This is the first large-scale, prospective study employing strictly defined criteria to assess the prevalence and incidence of peripheral nerve disease in type 1 Gaucher disease. The systematic, peripheral neurological evaluations in this type 1 Gaucher disease population identified sensory motor axonal polyneuropathy in 11 (10.7%) patients, and a mononeuropathy of the ulnar nerve at the elbow in 2 (1.9%) patients at baseline. Furthermore, six new cases of polyneuropathy were identified during a 2-year follow-up period (2.9 per 100 person-years). At baseline, 19 patients (18%) without neurological symptoms or signs had minor electrophysiological abnormalities. Follow-up studies revealed that these abnormalities were very early signs of peripheral neuropathy in 4 out of these 19 patients (21%). At baseline, a further 4 patients (3.9%) had electrophysiological abnormalities indicating a mild, sub-clinical polyneuropathy but did not have compatible neurological symptoms and/or signs. Follow-up studies were done in 1 of these patients, but no polyneuropathy had developed. In contrast, a group of 22 patients (21.4%) had normal electrophysiological results but displayed symptoms and signs of polyneuropathy, such as paraesthesias of the extremities and muscle cramps. Two of these patients (9%) developed polyneuropathy according to the definition.
The first important question is how these prevalence and incidence data compare with rates in the general population. For this purpose we chose two approaches: comparison with a small cohort at the Academic Medical Centre that underwent completely identical diagnostic tests, and the extraction of data from the available literature. The first approach revealed a prevalence of polyneuropathy in the general population of 0%.
The data from our observational cohort study are best compared with data from population-based and case-control studies that used comparable strict criteria to define polyneuropathy. These studies estimated the prevalence of polyneuropathy in the general population at 0.09 and 1.3%, respectively. The first estimate might be an underestimation, as only hospital-referred patients were in the numerator, while the denominator was made up of the total population in the referral area of the hospital. The second estimate is derived from studies in which the composition of control groups (i.e. hospital staff, spouses of veterans) is mostly not representative of the general population, which makes the interpretation of these data difficult. Studies using a less strict definition of polyneuropathy estimated the prevalence of polyneuropathy between 1.0 and 3.7%, which is almost certainly an overestimation. Therefore, the actual prevalence of polyneuropathy in the general population probably lies between 0.09 and 1.3%. Compared with these data, type 1 Gaucher disease patients clearly have a higher prevalence of polyneuropathy (Fig. 1) . Even if the four patients who were diagnosed at baseline with polyneuropathy and a concomitant disease that is associated with polyneuropathy are omitted, the prevalence of polyneuropathy in type 1 Gaucher disease patients would still be increased (7/99 = 7.1%).
The same observation is made for incidence data. Only a few studies reported on incidence of polyneuropathy with a wide range of incidence rates due to difference in study type, study population and diagnostic criteria. In the two studies that used electrophysiological confirmation, the incidence was clearly much lower than for the type 1 Gaucher disease population. When polyneuropathy is defined on symptoms and signs alone, this incidence is much higher and probably overestimated, but even compared with these data, there still is a higher incidence in patients with type 1 Gaucher disease.
Patients in our cohort with type 1 Gaucher disease with polyneuropathy were older than those without, in line with data from large-scale epidemiological studies (IGPSG, 1995) . Notably, however, the mean time from diagnosis was similar between polyneuropathy and non-polyneuropathy patients, suggesting that type 1 Gaucher disease was diagnosed later in life in patients with a polyneuropathy. The dosage of enzyme-replacement therapy was lower in patients with a polyneuropathy, making it unlikely that enzyme-replacement therapy by itself has any bearing on the occurrence of polyneuropathy. These findings suggest that either the clinical course/severity of type 1 Gaucher disease was milder in patients with polyneuropathy or it was detected at a later stage of disease.
The aetiology of polyneuropathy related to type 1 Gaucher disease has not yet been elucidated, although certain associated conditions may predispose patients to develop neurological disease. Relevant conditions might include monoclonal gammopathies, vitamin B 12 deficiency and diabetes mellitus (Gielchinsky et al., 2001; Mygland and Monstad, 2001; de Fost et al., 2008; Silberman and Lonial, 2008) . However, analysis of patient narratives and laboratory investigations did not reveal a consistent pattern of associated conditions in those with polyneuropathy. Only four patients had possible relevant conditions, involving vitamin B 1 deficiency, folic acid deficiency, monoclonal gammopathy, type 2 diabetes mellitus, renal insufficiency, alcohol abuse and exposure to toxins related to profession.
The pathophysiology of nerve injury in Gaucher disease remains speculative but may be related to an imbalance in calcium homoeostasis. Elevated intraneuronal glucocerebroside concentrations have been shown to induce a 300% increase in calcium-induced calcium release by influencing the RyaR channel, which has been proposed as one of the mechanisms responsible for neuronal injury in the CNS of neuronopathic Gaucher disease (Lloyd-Evans et al., 2003) . Whether this mechanism plays a role in peripheral nerve injury is unknown, but increased intracellular calcium has been implicated in the pathophysiology of diabetic neuropathy and neuropathic pain (Hall et al., 2001; Yaksh, 2006; Finnerup et al., 2007) . The role of genotype is difficult to assess in this small group of patients. There was a relatively high number of N370S homozygotes in the polyneuropathy group, but these patients were also older, which is associated with a higher prevalence of polyneuropathy.
With respect to study limitations, our findings are based on a non-controlled, observational analysis and should be interpreted with a degree of caution. In addition, while electrophysiological studies represent a standard, objective measure, the neurological symptom survey is based on patient self-report, and thus is open to potential recall bias. However, we consider that findings from the type 1 Gaucher disease cohort can be extended to the type 1 Gaucher disease population as a whole. Patient medical histories, concomitant treatments and systemic Gaucher disease manifestations were comparable with published large-scale registry data (Charrow et al., 2000) . Participating centres were chosen for their broad coverage of eligible patients, and the distribution of polyneuropathy was proportional to patient inclusion at each centre. Selection bias was avoided by including all patients with confirmed type 1 Gaucher disease attending routine clinic visits, regardless of disease severity, concomitant medical conditions and most medical treatments. Study procedures were arranged to fit in with each patient's existing visit schedule, avoiding bias against patients with more clinical problems. Finally, the two-step, blinded, central assessment of polyneuropathy minimized the risk of misclassification errors.
Conclusion
In conclusion, polyneuropathy appears to be part of the natural course of disease in patients with type 1 Gaucher disease, highlighting the need for increased vigilance for peripheral neurological abnormalities. We recommend early, careful questioning of type 1 Gaucher disease patients regarding neurological symptoms in clinical practice. When polyneuropathy is suspected, thorough examination by an experienced neurologist should be sought. Finally, it should be noted that while these and other published data suggest that type 1 Gaucher disease has a neuronopathic component, the types of neurological symptoms and signs seen in type 1 Gaucher disease are very different from those seen in the type 2 and 3 Gaucher disease phenotypes (Biegstraaten et al., 2008) . 
